Current endocrine therapies for ER-α-positive breast cancer target the action of estrogen on breast cancer cells by using selective ER modulators such as tamoxifen [7,10], aromatase inhibitors such as exemestane [11], or pure antiestrogens such as fulvestrant [12]. Here, ESR1 is linked to breast carcinoma.